Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Chelsea Therapeutics International, Ltd. | v329747_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Chelsea Therapeutics International, Ltd. | v329747_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2012
| CHELSEA THERAPEUTICS INTERNATIONAL, LTD. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 000-51462 | 20-3174202 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer ID Number) |
| 3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277 |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code: (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On December 4, 2012, Chelsea Therapeutics International, Ltd. (the “Company”) issued a press release announcing the results of Study 306B, the Company’s Phase III trial evaluating the efficacy of Northera™ (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension associated with Parkinson’s Disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On December 4, 2012, the Company also hosted a conference call and webcast to discuss the Study 306B results. A copy of the slide presentation included in the webcast is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) Exhibits | ||
| Exhibit No. | Description | |
| 99.1 | Press release dated December 4, 2012. | |
| 99.2 | PowerPoint presentation of December 4, 2012. |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHELSEA THERAPEUTICS INTERNATIONAL, LTD. | ||
| By: | /s/ J. Nick Riehle | |
| J. Nick Riehle | ||
| Chief Financial Officer | ||
Dated: December 5, 2012
Exhibit Index
| (d) Exhibits | ||
| Exhibit No. | Description | |
| 99.1 | Press release dated December 4, 2012. | |
| 99.2 | PowerPoint presentation of December 4, 2012. |